Ann: Australian Clinical Trials Manager to replace European Role, page-13

Yes this is a critically important feature of Bisantrene. It also means that for Bisantrene to be a commercial success it doesn’t have to be better than the other anthracyclines on the market. Even it turned out to be no better or worse as a chemo agent than all the others, just solving the cardiotoxicity issue would be a major treatment breakthrough.

One feature that is not so obvious is Bisantrene seems to cause less alopecia (hair loss) than other chemo agents like Doxorubicin. For many breast cancer patients the worst side effect they report from their treatment is hair loss. More than 80% of Doxorubicin treated patients lose their hair, while with Bisantrene more than half suffer no hair loss.